Medicare is considering changing how it addresses certain combination products for price negotiation purposes, which could impact new subcutaneous cancer drug formulations. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
